A host of neuropsychiatric disorders are intrinsic to Parkinson disease or occur as a complication of the dopaminergic therapies. Here's what to look for.
FDA Grants Regenerative Medicine Advanced Therapy Designation to Kyverna's KYV-101 for Refractory Stiff-Person Syndrome
Episode 119: Utilizing the Syn-One Test to Diagnose Parkinson Disease
Advances in Therapeutic Management for Parkinson Disease and Essential Tremor
Paradigm Shift in Parkinson’s Disease Diagnosis
NeuroVoices: David Shprecher, DO, MSci, FAAN, on Current and Future Directions in Biomarker Testing for Atypical Parkinsonism
New FNIH Initiative Looks to Expedite Parkinson Disease Diagnosis Through Validated Biomarkers